These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 15114254)
1. Epinastine ophthalmic solution (Elestat). Med Lett Drugs Ther; 2004 Apr; 46(1181):35-6. PubMed ID: 15114254 [No Abstract] [Full Text] [Related]
2. Elestat (epinastine HCl ophthalmic solution 0.05%) as a therapeutic for allergic conjunctivitis. Trattler WB; Luchs J; Majmudar P Int Ophthalmol Clin; 2006; 46(4):87-99. PubMed ID: 17060795 [No Abstract] [Full Text] [Related]
3. Epinastine: topical ophthalmic second generation antihistamine without significant systemic side effects. Pradhan S; Abhishek K; Mah F Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1135-40. PubMed ID: 19630694 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Abelson MB; Gomes P; Crampton HJ; Schiffman RM; Bradford RR; Whitcup SM Clin Ther; 2004 Jan; 26(1):35-47. PubMed ID: 14996516 [TBL] [Abstract][Full Text] [Related]
5. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Ousler GW; Workman DA; Torkildsen GL Clin Ther; 2007 Apr; 29(4):611-6. PubMed ID: 17617284 [TBL] [Abstract][Full Text] [Related]
6. Epinastine in the management of ocular allergic disease. Friedlaender MH Int Ophthalmol Clin; 2006; 46(4):85-6. PubMed ID: 17060794 [No Abstract] [Full Text] [Related]
7. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Villareal AL; Farley W; Pflugfelder SC Eye Contact Lens; 2006 Dec; 32(6):272-6. PubMed ID: 17099387 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332 [TBL] [Abstract][Full Text] [Related]
9. Epinastine 0.05% ophthalmic solution in contact lens-wearing subjects with a history of allergic conjunctivitis. Nichols KK; Morris S; Gaddie IB; Evans D Eye Contact Lens; 2009 Jan; 35(1):26-31. PubMed ID: 19125045 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. Mah FS; Rosenwasser LJ; Townsend WD; Greiner JV; Bensch G Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and artificial tears in seasonal allergic conjunctivitis. Kamis U; Ozturk BT; Ozkagnici A; Gunduz K Acta Ophthalmol Scand; 2006 Feb; 84(1):148-9. PubMed ID: 16445458 [No Abstract] [Full Text] [Related]
12. The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis. Torkildsen G; Shedden A Curr Med Res Opin; 2011 Mar; 27(3):623-31. PubMed ID: 21250860 [TBL] [Abstract][Full Text] [Related]